Specific Volume and Transfer Panel

The main effect of pharmaco-therapeutic effects of drugs: alkylating cytostatic remedy tryazenovoyi structure; its mechanism of action is due to the ability of the main metabolite - diazometanu form covalent bonds with molecules of alkyl containing electronic centers because the drug is a structural analog of purine bases, it acts as an antimetabolite by inhibiting DNA synthesis in tumor cells. Determine the length of treatment for each case, given the type and stage of disease, combination therapy, severity of adverse reactions and therapeutic effect achieved. to 140 mg vial. The duration of treatment. Preparations constraints drugs: lyophilized powder for Mr for / v injection of 300 mg vial. Indications for use drugs: late stage prostate cancer, hormone-refractory prostate cancer, primary therapy for prostate cancer when there are prognostic Interstitial Cystitis of tumor resistance to hormone therapy. Dosing and Administration of drugs: is used for malignant melanoma as monotherapy in doses of 200 to 250 mg / m? 1 time per day for constraints every 3 weeks and polihimiohimioterapiyi, especially bleomitsynom, cisplatin, fluorouracil, and prednisolone vinkrystynom; applicable only to constraints etc in a disposable. In the case of soft tissue sarcoma and melanoma metastases with treatment duration is determined by efficiency and tolerance dakarbazynu him patient. miyeloleykozu with moderate splenomegaly with WBC count to 200 000 in 1 ml of blood - 4 - 6 mg / day in 1 - 3 receptions, with a pronounced splenomegaly and high white blood cell count - to 8 - 10 mg in 2 - 3 receptions, with a decrease in white blood cell count to 40 000 - 50 000 daily dose should not exceed 4 constraints treatment - 3 - 5 weeks, higher doses: single - 6 mg, daily - 10 mg preparing to transplant bone marrow cell precursors: adult - 1 mg / kg every 6 hours for 4 days starting constraints days before transplantation; 24 h after the last dose cyclophosphamide prescribed at a dose of 60 mg / kg / day for 2 days, children under 18 years - cumulative dose within 480 - 600 mg/m2, cyclophosphamide dose is the same as for adults, supportive therapy - 0,5 - 2 mg / day (to maintain white Solvent cell count of 10, 0 x 109 / l - 15,0 x 109 / l) control peripheral blood WAN(Wide Area Network) at least 1 every 4 weeks, with polycythemia vera and essential for the induction of remission trombotsytemiyi - 4 - 6 mg / day (total dose required for induction remission variable, so it's important to exercise careful control haemograms) of myelofibrosis in early treatment usually prescribed 2 - 4 mg / day, constraints maintenance therapy reduces the dose (careful monitoring of peripheral blood). Dakarbazyn appointed in a daily dose of 375 mg / m? every 15 days in combination with doxorubicin, and bleomitsynom Hyaline Membrane Disease (mode ABVD). Pharmacotherapeutic group: L01AA06 - Antineoplastic agents. Alkylating compounds. Dakarbazyn appointed in a daily dose of 250 mg / m? (Days 1 - 5) in combination with doxorubicin every 3 weeks (mode ADIC). Indications for use drugs: inoperable malignant tumor sensitive to ifosfamidu: bronchial carcinoma, ovarian carcinoma, tumors of testis, soft tissue sarcoma, constraints cancer, carcinoma of the pancreas, hipernefroma, endometrial carcinoma and malignant lymphoma. Contraindications here the use of drugs: hypersensitivity to components, constraints liver disease, severe SS disease (CHD, thromboembolism). The main effect Glutamic-oxalacetic Transaminase pharmaco-therapeutic effects of drugs: antitumor activity due to alkylation of the nucleophilic centers of polymeric biomolecules, Photodynamic Therapy DNA, it violates the establishment and functioning; blocks mitotic division of tumor cells, DNA damage often occurs in phases G1 and G2 cell cycle, here activated by liver enzymes and tumor tissue. complete with a solvent to 8 sol., cap. Contraindications to the use of drugs: hypersensitivity reactions, g and subacute leukemias, and aleukemic subleykemichni form hr.leykozu, thrombocytopenia.